Production (Stage)
Kezar Life Sciences, Inc.
KZR
$4.40
$0.020.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 7.00M | 7.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 7.00M | 7.00M |
| Cost of Revenue | 48.57M | 48.57M | 55.18M | 62.68M | 67.38M |
| Gross Profit | -48.57M | -48.57M | -55.18M | -55.68M | -60.38M |
| SG&A Expenses | 22.30M | 23.39M | 23.61M | 26.69M | 26.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.05M | 89.14M | 95.96M | 106.54M | 111.42M |
| Operating Income | -83.05M | -89.14M | -95.96M | -99.54M | -104.42M |
| Income Before Tax | -78.63M | -83.74M | -95.78M | -98.57M | -101.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.63 | -83.74 | -95.78 | -98.57 | -101.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.63M | -83.74M | -95.78M | -98.57M | -101.33M |
| EBIT | -83.05M | -89.14M | -95.96M | -99.54M | -104.42M |
| EBITDA | -82.02M | -88.10M | -94.90M | -98.46M | -103.36M |
| EPS Basic | -13.55 | -14.26 | -13.15 | -13.55 | -13.94 |
| Normalized Basic EPS | -8.34 | -8.78 | -7.56 | -7.81 | -8.18 |
| EPS Diluted | -13.55 | -14.26 | -13.15 | -13.55 | -13.94 |
| Normalized Diluted EPS | -8.34 | -8.78 | -7.56 | -7.81 | -8.18 |
| Average Basic Shares Outstanding | 29.19M | 29.16M | 29.13M | 29.11M | 29.07M |
| Average Diluted Shares Outstanding | 29.19M | 29.16M | 29.13M | 29.11M | 29.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |